ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Spondylarthritis and Psoriatic Arthritis - Pathogenesis, Etiology

Meeting: 2012 ACR/ARHP Annual Meeting

Abstract Number: 580
Changes in Sclerostin, Dickkopf-1 and Serum Markers of Inflammation, Cartilage and Bone Turnover in Patients with Axial Spondyloarthritis Treated with Adalimumab
Abstract Number: 581
Examining a Role for Th17 Regulation and Toll-Like Receptor Signaling in Psoriatic Arthritis
Abstract Number: 582
Proteomic Analysis of Synovial Tissue: A Unique Tool to Predict Response to Anti-TNF Alpha Therapy in Patients with Inflammatory Arthritis
Abstract Number: 583
Familial Aggregation and Heritability of Ankylosing Spondylitis in Taiwan: A Nationwide Population Study
Abstract Number: 584
Association of Platelet Endothelial Cell Adhesion Molecule-1 and â1 Integrin Gene Polymorphisms with Uveitis Development in Ankylosing Spondylitis
Abstract Number: 585
Relative Overexpression of Membrane-Bound Versus Soluble TNF in Human and Experimental Spondyloarthritis
Abstract Number: 586
High Prevalence of Anti-CD-74 Antibodies with Specificity for the Class II-Associated Invariant Chain Peptide in Patients with Axial Spondyloarthritis but Not in Controls
Abstract Number: 587
Brain MRI and Psychophysics Analysis Demonstrate Neuropathic Pain to Be a Component of Back Pain in Ankylosing Spondylitis
Abstract Number: 588
Discovery of Two Public T Cell Receptor Clonotypes in B27+ Ankylosing Spondylitis by Deep Repertoire Sequence Analysis
Abstract Number: 589
NGF and Trka: A Novel Therapeutic Target in Chronic Inflammation
Abstract Number: 590
The Association Between KIR3DL1 Alleles and Psoriatic Arthritis
Abstract Number: 591
Structural Progression of Ankylosing Spondylitis Associated with Elevation in Two NOVEL, Inflammatory Biomarkers; Matrix Metalloproteinase and Cathepsin-Derived
Abstract Number: 592
Two Novel Diagnostic Biomarkers of Cartilage Degradation and Connective Tissue Inflammation Are Predictive of Disease Progression in Ankylosing Spondylitis
Abstract Number: 593
DKK1 Serum Level Is Increased in Recent Spondyloarthritis and Is Associated with Higher Prevalence of Syndesmophytes. Sclerostin Is Highly Correlated with Age. Data From the DESIR Cohort
Abstract Number: 594
Evidence of Human Leucozyte Antigen-B27 in Healthy Individuals and Patients with Uveitis Is a Risk Factor for Alterations in Bone Metabolism
Abstract Number: 595
A Genomewide Association Study of Anterior Uveiti
Abstract Number: 596
Evolution of Atherosclerosis in Psoriatic Arthritis: Is the Former an Independent Inflammatory Process?
Abstract Number: 597
Investigating the Genetic Association Between ERAP1 and Spondyloarthritis
Abstract Number: 598
The Non-Synonymous Polymorphism IL23R Arg381Gln Is Associated with Ankylosis in Spondyloarthritis
Abstract Number: 599
LIGHT (TNFSF14), Cathepsin K, DKK-1 and Sclerostin in Ankylosing Spondylitis: Osteoclast/OSTEOBLAST  Imbalance Unrelated to Disease Activity and Effect of ANTI-TNFα Treatment On the WNT/β Catenin Pathway
Abstract Number: 600
Regulatory T Cells in Spondyloarthritis (SpA) Animal Model and Modulatory Role of Inducible Costimulator (ICOS)
Abstract Number: 601
Bath Ankylosing Spondylitis Functional Index (BASFI) Is a Better Indicator of Poor Quality of Life Than Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in Ankylosing Spondylitis: Results From SIRAS – the Scotland and Ireland Registry for Ankylosing Spondylitis

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology